Versant Venture Management, LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001560009

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q3 2026 · 8 positions · Total reported value $109.10M · Top-10 concentration 100.0% · Updated 2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

Turnover: 12.5% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -44.9% · vs SPY -47.0% · Prev Value $162.61M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -13.5% · vs SPY -15.6% · Latest Value $109.10M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Versant Venture Management, LLC disclosed 8 equity positions with a combined reported value of $109.10M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q3 2026 were GLUE ($37.95M), IPSC ($20.80M), CTNM ($17.35M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Versant Venture Management, LLC opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 12.5% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Versant Venture Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Versant Venture Management, LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 8 US equity positions with a combined value of $162.61M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 8 positions · $162.61M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: GLUE (MONTE ROSA THERAPEUTICS INC) at 47.3%
  • Average position size: $20.33M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 reduced
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively rebalancing with a bullish tilt on biotech/therapeutics, evidenced by a new significant position (CTNM) and no reductions except for underperforming SKYE. The sector remains concentrated in Health Care, suggesting a focused view on clinical-stage biotech. 2. Key moves: - Added: CTNM (10.43% weight increase, +138.2% shares). - Reduced: SKYE (0.49% weight decrease, -87.5% shares). - No new positions (0 added), and no other changes despite weight shifts (price-driven). 3. Portfolio structure: Highly active, concentrated (top 10 = 99.99% of value), with extreme Health Care bias (100%). High risk appetite, holding small-cap clinical-stage biotechs with binary outcomes. 4. Per-holding one-liner: - GLUE: MONTE ROSA THERAPEUTICS (T-cell therapies, unverified). - IPSC: Century Therapeutics (stem cell-derived T-cells, unverified). - CTNM: CONTINEUM THERAPEUTICS (immuno-oncology, unverified). - JBIO: JADE BIOSCIENCES (T-cell engagers, unverified). - LENZ: Lenz Therapeutics (ophthalmology gene therapy, unverified). - CRSP: CRISPR THERAPEUTICS (gene editing, verified). - SKYE: Skye Bioscience (retinal diseases, unverified). - TPST: Tempest Therapeutics (oncology, unverified). 5. Style summary: Concentrated biotech fund with high conviction in clinical-stage therapeutics, selectively adding winners (CTNM) and cutting losers (SKYE).

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 00:06

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.18M $37.95M 34.78%
34.78%
Hold
2 12.17M $20.80M 19.07%
19.07%
Hold
3 1.29M $17.35M 15.90%
15.90%
Add
4 991.78K $13.93M 12.77%
12.77%
Hold
5 2.66M $10.20M 9.35%
9.35%
Hold
6 148.83K $8.23M 7.55%
7.55%
Hold
7 250.96K $404.05K 0.37%
0.37%
Reduce
8 269.77K $225.07K 0.21%
0.21%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 100% R 100% F1 100% (modelled on 2026-Q2; 8/10 hit)

Historical Backtest (11 quarters)

Avg precision 93% · recall 92% · F1 92% · avg rank error 1.6 · Top-10 turnover 8%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 86% 86% 86% RYZB · CRSP · RPTX · GRTSQ · PASG · ADVM · ALGS CRSP · SKYE · RPTX · GRTSQ · ADVM · PASG · ALGS
2024-Q2 100% 88% 93% CRSP · SKYE · RPTX · GRTSQ · PASG · ADVM · ALGS CRSP · CTNM · SKYE · RPTX · ADVM · PASG · GRTSQ · ALGS
2024-Q3 75% 100% 86% CRSP · CTNM · SKYE · RPTX · PASG · ADVM · GRTSQ · ALGS CRSP · CTNM · RPTX · SKYE · ADVM · GRTSQ
2024-Q4 83% 71% 77% CRSP · CTNM · RPTX · SKYE · ADVM · GRTSQ GLUE · CRSP · CTNM · SKYE · RPTX · TPST · ADVM
2025-Q1 100% 100% 100% GLUE · CRSP · CTNM · SKYE · RPTX · TPST · ADVM GLUE · CRSP · CTNM · SKYE · RPTX · TPST · ADVM
2025-Q2 100% 88% 93% GLUE · CRSP · CTNM · SKYE · RPTX · TPST · ADVM GLUE · CRSP · JBIO · SKYE · RPTX · CTNM · TPST · ADVM
2025-Q3 100% 89% 94% GLUE · CRSP · JBIO · SKYE · RPTX · CTNM · TPST · ADVM LENZ · GLUE · JBIO · CRSP · SKYE · CTNM · RPTX · TPST · ADVM
2025-Q4 78% 100% 88% LENZ · GLUE · JBIO · CRSP · SKYE · CTNM · RPTX · TPST · ADVM GLUE · LENZ · JBIO · CRSP · CTNM · SKYE · TPST
2026-Q1 100% 88% 93% GLUE · LENZ · JBIO · CRSP · CTNM · SKYE · TPST GLUE · IPSC · LENZ · JBIO · CTNM · CRSP · SKYE · TPST
2026-Q2 100% 100% 100% GLUE · IPSC · LENZ · JBIO · CTNM · CRSP · SKYE · TPST GLUE · IPSC · JBIO · LENZ · CTNM · CRSP · SKYE · TPST
2026-Q3 ★ 100% 100% 100% GLUE · IPSC · JBIO · LENZ · CTNM · CRSP · SKYE · TPST GLUE · IPSC · CTNM · JBIO · LENZ · CRSP · SKYE · TPST

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-13. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-13 Trading days32 Holdings2 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.

Portfolio return-22.29%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return-8.58%vs benchmark
Barra annualised vol63.0%Model estimate
Realised vol114.8%Annualised in window
Weighted beta1.32Raw exposure
Factor / specific risk36% / 64%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)61.772.984.095.1106.210-0110-2311-13Versant Venture Management, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-22.29%Disclosed long book
QQQ synthetic benchmark-13.72%Liquidity-weighted constituents
Model universe, equal weight+0.30%Opportunity-cost reference
Excess return-8.58%Portfolio − benchmark
Arithmetic return sum-15.25%Difference vs compounded is the cross term
Weighted raw beta1.32Weighted holding betas
Realised volatility (annualised)114.80%Daily returns in window
Barra model volatility (annualised)62.96%Factor + specific
Factor share of variance36.1%Barra factors
Specific share of variance63.9%Stock residuals
Reported value$25.6M13F long US equity

2. Return attribution

The -15.25% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +0.64% 4.2%
Momentum & Growth 3 -0.48% -3.1%
Volatility & Tail Risk 7 -13.12% -86.0%
Industry 12 +8.12% 53.3%
Specific 1 -10.41% -68.3%
Return attribution (style + industry, %)-18.3-9.1+0.0+9.1+18.3Liquidity+0.36Kurtosis-0.39Leverage (Downside Vol)+0.56Short-term Reversal+0.86Amihud Illiquidity-1.11Growth-1.23Beta+2.29Non-linear Size+2.81Size+3.04Skewness-3.66Mid Cap-4.52Residual Volatility+5.00Health Care+8.12Historical Volatility-16.90
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +8.12% +8.12% 53.3%
Residual Volatility Style +1.88 +2.66% +5.00% 32.8%
Size Style -1.66 -1.83% +3.04% 19.9%
Non-linear Size Style +3.07 +0.91% +2.81% 18.4%
Beta Style +0.47 +4.85% +2.29% 15.0%
Short-term Reversal Style +1.10 +0.79% +0.86% 5.7%
Leverage (Downside Vol) Style -0.31 -1.82% +0.56% 3.7%
Liquidity Style +1.65 +0.22% +0.36% 2.3%
Turnover Style -0.01 -4.77% +0.07% 0.5%
Momentum Style +0.03 -3.34% -0.11% -0.7%
Kurtosis Style -0.06 +6.97% -0.39% -2.6%
Amihud Illiquidity Style +2.75 -0.40% -1.11% -7.3%
Growth Style -0.79 +1.57% -1.23% -8.1%
Skewness Style +0.87 -4.21% -3.66% -24.0%
Mid Cap Style +2.67 -1.69% -4.52% -29.6%
Specific Specific — — -10.41% -68.3%
Historical Volatility Style +1.31 -12.86% -16.90% -110.8%

3. Risk attribution

Annualised volatility is 62.96%; factor risk explains 36.1% of variance and specific risk 63.9%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-69.0-34.5+0.0+34.5+69.0Leverage (Downside Vol)-0.34Short-term Reversal+0.37Skewness+0.55Size+1.65Beta+2.09Liquidity+3.20Non-linear Size+3.73Residual Volatility+4.18Mid Cap+6.15Health Care+7.21Historical Volatility+7.28Specific+63.88
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 63.9% +40.22% 40.2%
Historical Volatility Style +1.31 7.3% +4.58% 4.6%
Health Care Industry +1.00 7.2% +4.54% 4.5%
Mid Cap Style +2.67 6.2% +3.87% 3.9%
Residual Volatility Style +1.88 4.2% +2.63% 2.6%
Non-linear Size Style +3.07 3.7% +2.35% 2.4%
Liquidity Style +1.65 3.2% +2.01% 2.0%
Beta Style +0.47 2.1% +1.32% 1.3%
Size Style -1.66 1.6% +1.04% 1.0%
Skewness Style +0.87 0.6% +0.35% 0.3%
Short-term Reversal Style +1.10 0.4% +0.23% 0.2%
Leverage (Downside Vol) Style -0.31 -0.3% -0.22% -0.2%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-2.1-0.70.72.13.5Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.66 +2.10 -3.76
Non-linear Size +3.07 +1.68 +1.39
Mid Cap +2.67 +0.13 +2.54
Beta +0.47 +1.29 -0.82
Momentum +0.03 +0.72 -0.68
Short-term Reversal +1.10 -0.64 +1.74
Residual Volatility +1.88 -0.40 +2.28
Historical Volatility +1.31 +0.86 +0.45
Liquidity +1.65 +0.11 +1.53
Amihud Illiquidity +2.75 +1.16 +1.60
Turnover -0.01 +0.21 -0.22
Growth -0.79 +0.58 -1.37
Leverage (Downside Vol) -0.31 +0.14 -0.45
Skewness +0.87 +0.24 +0.63
Kurtosis -0.06 +0.21 -0.27
Max Drawdown +0.01 -0.08 +0.09

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -19.18% +4.32% +14.12% -14.12% +14.12%
Communication Services 0.0% 2.6% +0.00% -15.54% +0.06% +0.41% -0.41% +0.41%
Utilities 0.0% 0.8% +0.00% +11.58% -0.20% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.58% -0.24% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +5.56% -1.66% -0.49% +0.49% -0.49%
Industrials 0.0% 11.1% +0.00% +7.16% -2.27% -0.80% +0.80% -0.80%
Health Care 100.0% 1.7% -25.60% +9.16% +22.08% -0.60% -34.16% -25.76%
Total +21.99% +12.38% -47.14% -12.77%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
CTNM CONTINEUM THERAPEUTICS INC Health Care 67.81% -26.53% -17.99% Add
CRSP CRISPR THERAPEUTICS AG Health Care 32.19% -23.64% -7.61% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 CRSP Health Care 32.19% -23.64% -7.61%
2 CTNM Health Care 67.81% -26.53% -17.99%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned -22.29%, versus -13.72% for the QQQ synthetic benchmark — an excess of -8.58%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +8.12%, Residual Volatility +5.00%, Size +3.04%; the largest drags came from Historical Volatility -16.90%, Mid Cap -4.52%, Skewness -3.66%. Specific (stock-level) return contributed -10.41%.
  3. Risk attribution: Barra model volatility is 62.96% annualised; factor risk explains 36% of variance and specific risk 64%. The largest factor risk sources are Historical Volatility 7.3%, Health Care 7.2%, Mid Cap 6.2%.
  4. Style tilt: size -1.66, momentum +0.03, volatility +1.31, liquidity +1.65; the weighted raw beta is 1.32. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.99%, selection +12.38% and interaction -47.14%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Versant Venture Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Versant Venture Management, LLC reported 8 equity positions worth $109.10M in aggregate; its largest disclosed positions were GLUE ($37.95M), IPSC ($20.80M), CTNM ($17.35M).

How large is Versant Venture Management, LLC's portfolio?

Versant Venture Management, LLC reported $109.10M of long equity holdings across 8 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Versant Venture Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/versant-venture-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →